The FDA has granted orphan drug designation to INSYS Therapeutics, Inc. for its pharmaceutical cannabidiol oral solution (CBD). Insys started dosing pediatric epilepsy patients in a Phase 1 safety trial and also announced that a pharmacokinetic study is being conducted on pediatric epilepsy patients. The clinical trial will evaluate INSYS’s pharmaceutical CBD oral solution at three different dosage strengths. This is INSYS’s first in-patient dosing with its pharmaceutical CBD formulation.